The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Our immune system is great at fighting many types of cancer, but it struggles to see prostate tumors. While new treatments have been game-changers for lung cancer and skin cancer, prostate cancer ...

The average age of men who get diagnosed is 67.

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients. Prostate cancer is the most common cancer among men ...

At 77 years old, Tyson Johnson has been in treatment for metastatic prostate cancer for more than 20 years. “I’m the healthiest dead man you’ve ever seen,” the Carthage resident said jokingly as he ...

Dr. Daniel P. Petrylak discussed recent developments in prostate cancer care, emphasizing the importance of genetic testing and personalized treatment. Dr. Daniel P. Petrylak, a professor of Medicine ...

Florida State University researchers are working on new approaches to deciphering genetic data that may lead to new, more targeted prostate cancer treatments. Prostate cancer, which affects one in ...